Condition: Lupus Nephritis · Lupus Erythematosus · Sponsor: Red de Terapia Celular
The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) obtained from bone marrow for the treatment of adults with active proliferative lupus nephritis. The objective of this study is to evaluate the efficacy of mesenchymal stem cells (MSCs) in achieving a full or partial response in the treatment of Lupus Nephritis (LN) during its induction period.
This description comes directly from the study's public registry record.
Julia Barbado, MD, PhD · +34 983 420400 · jbarbadoa@saludcastillayleon.es
Margarita González-Vallinas, PhD · +34 983 184688 · mgvallinas@ibgm.uva.es
Always discuss trial participation with your own doctor first.
| University Hospital Río Hortega | Valladolid, Valladolid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03673748